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Metformin increases cortisol regeneration by
11HSD1 in obese men with and without type 2
diabetes mellitus
Anna J Anderson1, Ruth Andrew1, Natalie Z Homer1, Gregory C Jones1,
Kenneth Smith1, Dawn E Livingstone1, Brian R Walker1, Roland H Stimson1
1University/ BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United
Kingdom STRUCTURED
Context: Themechanism of action ofmetformin remains unclear. Given regulation of the cortisol-
regenerating enzyme 11HSD1 by insulin, and limited efficacy of selective 11HSD1 inhibitors to
lower blood glucose when co-prescribed with metformin, we hypothesized that metformin re-
duces 11HSD1 activity.
Objective: To determinewhethermetformin regulates 11HSD1 activity in vivo in obesemenwith
and without type 2 diabetes.
Design: Double blind randomised placebo controlled crossover study
Setting: A hospital clinical research facility
Participants:Eightobesenon-diabeticmen (OND)andeightobesemenwith type2diabetes (ODM)
Intervention: Participants received 28 days of metformin (1g twice daily), placebo, or (in the ODM
group) gliclazide (80mg twice daily) in random order. A deuterated cortisol infusion at the end of
each phase measured cortisol regeneration by 11HSD1. Oral cortisone was given to measure
hepatic 11HSD1activity in theODMgroup. Theeffectofmetforminon11HSD1wasalsoassessed
in human hepatocytes and SGBS adipocytes.
Main outcome measures: The effect of metformin on whole body and hepatic 11HSD1 activity.
Results:Whole body 11HSD1 activity was25%higher in the ODM thanOND group.Metformin
increased whole body cortisol regeneration by 11HSD1 in both groups compared with placebo
and gliclazide, and tended to increase hepatic 11HSD1 activity. In vitro, metformin did not in-
crease 11HSD1 activity in hepatocytes or adipocytes.
Conclusions:Metformin increases whole body cortisol generation by 11HSD1 probably through
an indirect mechanism, potentially offsetting othermetabolic benefits ofmetformin. Co-prescrip-
tion with metformin should provide a greater target for selective 11HSD1 inhibitors.
Obese men with and without type 2 diabetes received 28 days of metformin or placebo then
underwent a deuterated cortisol infusion to measure 11HSD1 activity. Metformin increased
whole body 11HSD1 activity in both groups.
Metformin is the mainstay of treatment in obese pa-tients with type 2 diabetes mellitus (T2DM), yet
themechanismof action remains unclear.Metformin low-
ers glucose concentrations in part by suppressing hepatic
gluconeogenesis (1), an effect thought to be primarily me-
diated through inhibition of the respiratory-chain com-
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plex Iwith subsequent activationofAMPK(2).Additional
mechanisms contributing to the glucose lowering effect of
metformin have been proposed, such as the organic cation
transporter Oct1 which enhances the action of metformin
in the liver, while metforminmay antagonise the effects of
glucagon (reviewed in (3)). A further potential molecular
target for metformin action has been identified following
thediscoveryof altered tissue cortisol regulation inobesity
and T2DM (4–6).
While circulating cortisol is controlled centrally by the
hypothalamic-pituitary-adrenal (HPA) axis, tissue gluco-
corticoid levels are further regulated by the 11-hydrox-
ysteroid dehydrogenase enzymes. The type 2 isozyme
(11HSD2) converts cortisol to inactive cortisone, mod-
ulating activation of mineralocorticoid receptors in rele-
vant tissues such as kidney (7). The type 1 isozyme
(11HSD1) is more abundant across metabolically active
tissues, particularly in the liver and adipose tissue, and
primarily converts cortisone to cortisol (8). Transgenic
mice overexpressing 11HSD1 in adipose tissue or liver
develop features of the metabolic syndrome such as obe-
sity, glucose intolerance and dyslipidaemia (9, 10). In hu-
man obesity, hepatic 11HSD1 activity is decreasedwhile
adipose tissue 11HSD1 is increased, resulting in similar
whole body cortisol regeneration by 11HSD1 compared
to lean individuals (4, 5, 11). In contrast, in obesity-asso-
ciated T2DMcortisol regeneration by 11HSD1 inwhole
body is increased and not decreased in the liver (6, 12); as
insulin suppresses hepatic 11-HSD1 activity (13) the im-
paired insulin signaling associated with T2DMmay drive
the lack of suppression of hepatic 11HSD1 in this group.
These results highlight the potential benefit of inhibiting
11HSD1 as a novel treatment for obesity-associated
T2DM.
Numerous selective 11HSD1 inhibitors have been de-
veloped (reviewed in (14)), however results from the pub-
lished phase 2 trials have been disappointing. The vast
majority of patients participating in these trials were co-
prescribedmetformin.We hypothesized that the improve-
ment in insulin sensitivity induced by metformin may de-
crease hepatic 11HSD1 activity and limit the efficacy of
11HSD1 inhibition. Therefore, we tested whether met-
formin regulates cortisol regeneration by 11HSD1 in
obese individuals with T2DM (the target group for selec-
tive 11-HSD1 inhibitors) and in obese euglycaemic in-
dividuals (who have suppressed hepatic 11-HSD1unlike
those with T2DM), using a deuterated cortisol infusion to
measure whole body 11HSD1 activity (15).
Materials and Methods
In vivo study protocol
Eight obese nondiabetic (OND) men and eight obese men
with T2DM (ODM) were recruited to this double blind placebo
controlled crossover study. Inclusion criteria were: body mass
index (BMI) 30 kg/m2; aged 18–70 years; alcohol intake 21
U per week; no exogenous glucocorticoid exposure in the pre-
ceding 6months; normal screening blood tests (full blood count,
kidney, liver and thyroid function, and normal glucose in OND
group); 5% change in body weight over the preceding 3
months; not on any medications known to regulate cortisol me-
tabolism (eg, antifungals, 5-reductase inhibitors or opiates);
glycated hemoglobin A1c (HbA1c)10% (86mmol/mol) if diet
controlled or  8% (64 mmol/mol) if on metformin mono-
therapy (ODM group only). Informed consent was obtained
from all participants and approval was obtained for this study
from the local research ethics committee. ODM participants re-
mained on their other prescribed medications (eg, statins, anti-
hypertensives) throughout the study. Participants were random-
ized to receive 28 days of either placebo or metformin 1 g twice
daily; in order to account for any confounding effect of improv-
ing glycaemic control on 11HSD1, theODMgroup underwent
a thirdphase taking the sulfonylureagliclazide80mg twicedaily.
There was a three day washout period between phases.
At the end of each phase subjects attended the Clinical Re-
searchFacility at 0830hafter overnight fast.Measurementswere
performed of height and weight and baseline bloods were taken
for fasting glucose, insulin and HbA1c. To measure whole body
11HSD1 activity, cortisol (containing 20% 9,11,12,12-[2H]4-
cortisol (D4-cortisol) (Cambridge Isotopes, Andover, MA)) was
infused at 1.74 mg/hr for 4 hours following an initial 3.5 mg
bolus (16). In brief, D4-cortisol is converted to 9,12,12-[2H]3-
cortisone (D3-cortisone) by 11HSD2 due to the loss of the
deuterium on the 11th carbon. D3-Cortisone is then regenerated
to D3-cortisol by 11HSD1. Once in steady state, dilution of
D4-cortisol by D3-cortisol is a specific measure of cortisol re-
generation by 11HSD1. Blood samples were taken at regular
intervals once steady statewas achieved (t150minutes) (Figure
1). In the ODM group, after samples had been collected for
steady state measurements, oral cortisone (5 mg) was given at
180 minutes and conversion to cortisol measured over the next
hour to determine hepatic 11HSD1 activity (6).
Effects of metformin on 11HSD1 activity in vitro
Human primary hepatocytes (Bioreclamation IVT, Frank-
furt, Germany) were cultured according to the manufacturer’s
instructions.Human Simpson-Golabi-Behmel syndrome (SGBS)
preadipocytes were cultured as previously described (17). Three
days after plating (hepatocytes), or following completion of dif-
ferentiation on day 12 (adipocytes), cells were cultured for 24
hours in either vehicle, 100 nM, 1 M, 10 M, 100 M, 1 mM
or 10 mMmetformin hydrochloride (Sigma, Poole, UK). There-
after, cells were incubated with medium containing 1 M cor-
tisone (enriched with 20 nM 1,2-[3H]2-cortisone (GE Health-
care, Little Chalfont, U.K.)) for either 120 (hepatocytes) or 240
minutes (adipocytes) at 37°C to measure conversion to cortisol.
Laboratory analysis
Biochemical measurements
Plasma glucose was measured using a colorimetric assay and
insulin by immunoassay usingAbottArchitect analysers.HbA1c
was measured by HPLC (HA8180 analyzer, Menarini Diagnos-
tics, Berkshire, UK). Endogenous and tracer glucocorticoids
(cortisol, D4-cortisol, D3-cortisol, cortisone and D3-cortisone)
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were measured by liquid chromatography tandem mass spec-
trometry (LC-MS/MS) as previously described (6).
Metformin and gliclazide were extracted from plasma (100
L) using an SLE plate (Biotage, UK) following enrichment
withD6-metformin andD3-glyburide as internal standards (200
ng). Calibration standards ranged from 0.5–1000ng. Analytes
were eluted, reduced to dryness under nitrogen (40°C) and re-
constituted in water/acetonitrile (100 L; 80:20, v/v)). Analysis
was carried out by liquid chromatography tandem mass spec-
trometry (LC-MS/MS). Chromatographic separation was on an
ACEExcel Super2C18 column (1003mm;2m)protected by
a Kinetex KrudKatcher® (Phenomenex, UK) and detected on a
5500 QTrap (Seiex, UK) operated by selective reaction moni-
toring in positive electrospray ionization mode. The mobile
phasewas0.1%formic acid inwater (A), 0.1%FA inacetonitrile
(B) at 0.2 mL/min, 30°C. Gradient elution from 20%–90% B
where metformin and D6-metformin eluted at 1.1 minute and
gliclazide and D3-glyburide eluted at 2.0 and 2.3 mins with a
total run time of 5 minutes. Transitions
monitored for were m/z 130.1 3
60.1and m/z 136.2 3 60.1 for met-
formin and D6-metformin, respectively
andm/z 324.23153.1 andm/z 497.13
372.1, for gliclazide and d3-glyburide,
respectively.
Analysis of tritiated steroids
Tritiated steroids were extracted
from200L ofmediumusingmethanol.
[3H]2-Cortisone and [
3H]2-cortisol were
quantified by HPLC with online -scin-
tillation counting (Berthold LB509 de-
tector; Berthold Technologies,
Harpenden, U.K.). Samples were ana-
lyzed inquadruplicate.Total proteinwas
measured in each sample using the
DCTMprotein assay (Bio-Rad,CA,USA)
and cortisol production rates normalized
for protein content.
Cortisol kinetics
Cortisol kinetics were calculated as
previously described (6). Steady state
samples were collected from 150 to 240
minutes in theONDgroup and from150
until 180 minutes (time of cortisone in-
gestion) in the ODM group. Rate of ap-
pearance (Ra) of endogenous cortisol in
whole body during steady state was cal-
culated using Equation 1:
Ra Cortisol 
D4Cortisol infusion rate
D4Cortisol/Cortisol ratio
Cortisol infusion rate (1)
Ra D3-cortisol (a specific measure of
cortisol regeneration by 11HSD1) was
calculated using Equation 2:
Ra D3  Cortisol 
D4Cortisol infusion rate
D4Cortisol/D3Cortisol ratio
(2)
Clearance of D4-cortisol was calcu-
latedbydividing theD4-cortisol infusion
rate by the steady state D4-cortisol concentration. The rate of
appearance of cortisol following oral cortisone ingestion (amea-
sure of hepatic 11HSD1 activity) in the ODM group was cal-
culated using Steele’s non steady state equation (Equation 3)
where t denotes time, V is the volume of distribution, C(t) is the
total cortisol concentration at time (t) and E(t) is the tracer to
tracee ratio (D4 cortisol/cortisol). Volume of distribution for
cortisol was taken as being 12L as in previous studies (12, 18).
Ra Cortisol  D4Cortisol infusion rateE(t) 
V
C(t)
1E(t)

dE(t)
dt
E(t)  (3)
Figure 1. Endogenous and tracer cortisol measurements Data are mean  SEM for
metformin (black squares), gliclazide (open triangles) and placebo (open circles) on A,D) plasma
cortisol, B,E) D4-cortisol enrichment and C,F) D4-cortisol/D3-cortisol ratio in obese nondiabetic
(OND, n  8, panels A-C) and obese diabetic (ODM, n  8, panels D-F) groups.
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Statistical analysis
Data are presented as mean SEM. Power calculations were
performed using prior datawhich indicated that the difference in
the response of matched pairs was normally distributed with
standard deviation 1.21 (16). Eight subjects per group pro-
vided 	 85% power to detect a 10% difference in the rate of
appearance of d3-cortisol with a 0.05 probability of a Type I
error associated with this test. Data were analyzed using SPSS
version 21. Data were normally distributed using Kolmogorov-
Smirnov testing. Comparisons between 2 related samples were
performed using paired t tests and between 3 or more related
samples using repeatedmeasuresANOVAwith post hoc Fisher’s
LSD testing. Comparisons between 2 unrelated samples were
performed using unpaired t tests. P  .05 was considered
significant.
Results
Anthropometric and
biochemical data
Subjects in the ODM group were
older and had higher fasting glucose
and HbA1C than the OND partici-
pants (Table 1). BMI was not differ-
ent between the two groups (P	 .2)
and body weight did not change be-
tween phases (data not shown). One
of theOND subjects developed tran-
sient diarrhea during the metformin
phase, no other side effects were re-
ported by any of the participants.
Metformin and gliclazide decreased
fasting glucose to a similar extent in
the ODM group with similar trends
in HbA1c, but metformin did not al-
ter fasting glucose in OND partici-
pants (Table 1). Metformin and gli-
clazide were only detected in the
plasma during the appropriate
phases (data not shown).
Cortisol kinetics
Fasting cortisol was similar be-
tweenOND andODMgroups and was unaltered bymet-
formin or gliclazide treatment (Figure 1A,D).
Steady state measurements
Steady state D4-cortisol enrichment was achieved after
150minutesofD4-cortisol infusion inbothgroups (Figure
1B,E).Metformin increased the rate of appearance of D3-
cortisol (RaD3-cortisol, a specific measure of whole body
11HSD1 activity) compared with placebo (both groups)
and gliclazide (ODM group only) (Figure 2B). Ra D3-
cortisol was higher in ODM compared with OND partic-
ipants. Ra cortisol (Figure 2A) and D4-cortisol clearance
Figure 2. The effect of metformin on 11HSD1 activity in vivo Data are mean 
SEM for the effect of metformin (black columns), gliclazide (bricked columns) and placebo (white
columns) on the rate of appearance (Ra) of A) Cortisol and B) D3-cortisol during steady state. C)
The effect of metformin (black squares), gliclazide (open triangles) and placebo (open circles) on
Ra cortisol following 5 mg oral cortisone ingestion in the ODM group. Phases were compared
using paired t tests in the OND group and repeated measures ANOVA with post hoc Fisher’s LSD
testing in the ODM group. Placebo-phase data in OND and ODM groups were compared using
the unpaired t test. *P  .05 vs placebo, $P  .05 vs metformin, # P  .05 vs OND group.
Table 1. Anthropometric and biochemical data
OND ODM
Placebo Metformin Placebo Metformin Gliclazide
Age (years) 43.6  4.6 65.8  0.8#
BMI (kg/m2) 37.4  2.6 37.3  2.8 34.2  1.1 34.2  1.2 34.6  1.1
Fasting glucose (mmol/liter) 5.6  0.6 5.3  0.2 10.8  1.0# 7.7  0.5* 7.0  0.6*
HbA1c (%/ mmol/mol) 5.7  0.2 (38.8  2.0) 5.7  0.2 (38.4  2.2) 7.2  0.2 (55.4  2.5)## 6.9  0.3 (52.4  3.0) 7.1  0.3 (53.6  3.6)
Fasting insulin (mU/liter) 17.1  5.1 10.6  2.2 24.2  9.7 24.9  10.3 21.4  7.5
HOMA-IR 5.0  1.9 2.5  0.6 9.4  3.2 7.0  2.2 7.2  1.7
Total cholesterol (mmol/liter) 4.5  0.4 4.7  0.6 3.5  0.2# 3.4  0.2 3.4  0.2
D4-Cortisol clearance (L/min) 0.5  0.1 0.6  0.1 0.5  0.1 0.5  0.1 0.6  0.1
Data are mean  SEM for data from obese non-diabetic (OND, n  8) and diabetic (ODM, n  8) participants. Phases were compared using paired
t tests in the OND group and repeated measures ANOVA with post-hoc Fisher’s LSD testing in the ODM group. Placebo-phase data for OND and
ODM groups were compared using unpaired t tests. *P  0.05 vs. placebo; #P  0.05, ##P  0.01 v OND group.
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(Table 1) rates were unaltered by either treatment and not
different between ODM and OND groups.
Nonsteady state measurement of hepatic 11HSD1
activity
Cortisol production by hepatic 11HSD1 was calcu-
lated using Equation 3 in the ODM group. Metformin
tended to increase Ra cortisol following oral cortisone
(P  .07) (Figure 2C).
Effect of metformin on 11HSD1 activity in vitro
[3H]2-Cortisol was readily detected in all samples fol-
lowing incubation. Metformin did not increase conver-
sionof [3H]2-cortisone to [
3H]2-cortisol in either the hepa-
tocytes or the adipocytes (Figure 3). In both the
hepatocytes and adipocytes, the highest metformin con-
centration (10 mM) decreased cortisol generation by
11HSD1.
Discussion
Contrary to our hypothesis, metformin increased whole
body cortisol regeneration by 11HSD1 in obese men
with and without T2DM. This substantial increase in Ra
D3-cortisol (15%) in both groups suggests that the liver
is the most likely tissue responsible as the liver accounts
for 	 90% of extra-adrenal cortisol production (8, 19).
Furthermore, metformin tended to increase conversion of
orally administered cortisone to cortisol (a measure of he-
patic 11HSD1 activity) in the ODM group; in one indi-
vidual where there was, surprisingly, no increase in either
circulating cortisone or cortisol concentrations following
oral cortisone ingestion, and removal of this subject’s data
led to a strongly significant increase in hepatic cortisol
generation on the metformin phase in the remaining 7
subjects (P .01). Adipose tissue and skeletal muscle are
alternative tissues which could be responsible, but this is
unlikely since the increase in Ra D3-cortisol induced by
metformin is greater than the contri-
bution of both tissues combined to
wholebodycortisol regenerationun-
der normal conditions (20).
In addition, we have determined
that whole body 11HSD1 activity
is increased in obese men with
T2DMcompared toobesemenwith-
out diabetes. There have been con-
flicting results from previous work
examining whether hepatic and
whole body 11HSD1 activity is al-
tered in T2DM (6, 12, 21), however
these results are consistent with the
interpretation that hepatic 11HSD1 is decreased in eu-
glycaemic obesity but not in obesity-associated T2DM (4,
22). While the ODM group were older which could be a
potential confounder, we have not observed any increase
in cortisol regeneration by 11HSD1with age in previous
studies (6, 16).
We hypothesized that insulin could mediate the effect
of metformin on 11HSD1 as insulin decreases hepatic
activity (13). Although it is possible that metformin may
have reduced insulin levels in the OND group, there was
no suggestion of metformin reducing insulin concentra-
tions in theODMgroup so it is unlikely that insulin drives
this regulation, while if changes in insulin sensitivity were
responsible wemay have expected to see a greater effect in
the ODM group. Similarly, alterations in glucose concen-
trations are not responsible as levels were similar during
the gliclazide phase without altering 11HSD1 activity.
Our invitrodata suggest this is not adirect effect, although
it is possible that longer incubations may have increased
cortisol generation by 11HSD1. Circulating metformin
concentrations are typically 10–40 M in humans (23)
while hepatic concentrations can reach 100–200 M in
rodents (24), meaning our in vitro metformin concentra-
tions encompassed the physiologically relevant range. It is
possible that the reduction in cortisol conversion at the
highest concentration was due to cytotoxicity, as met-
formin has been reported as cytotoxic in the millimolar
range although this is supraphysiological (25).
Recent work has shown that metformin decreases
ACTH secretion in humans (26) and reduces ACTH-stim-
ulated adrenal secretion (27). This is consistent with our
observation of enhanced peripheral regeneration of cor-
tisol and hence increased negative feedback to the HPA
axis; conversely, inhibition of 11HSD1 results in ele-
vatedACTH(14).However,wedidnot confirm reduction
in clearance of cortisol or decrease in total (adrenal plus
11HSD1) cortisol production with metformin, albeit
these may be more insensitive measurements.
Figure 3. The effect of metformin on 11HSD1 activity in vitro Data are mean 
SEM for the rate of cortisol production in A) primary human hepatocytes and B) human SGBS
adipocytes following incubation with vehicle (white columns) or increasing doses of metformin
(black columns) for 24 hours (n  4 per concentration). Comparisons were performed using
repeated measures ANOVA with post hoc Fisher’s LSD testing. *P  .05 vs vehicle.
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Our initial hypothesis was that suppression of
11HSD1 activity by metformin could be the reason for
the lack of efficacy of selective 11HSD1 inhibitors in
improving HbA1C (14). However, metformin increased
11HSD1 activity, an effect which could offset the other
metabolic benefits of metformin and potentially enhance
any benefit of 11HSD1 inhibitors. This does not appear,
therefore, to be a reason for the lack of efficacy of these
drugs.
In conclusion, metformin increases whole body and
likely hepatic regeneration of cortisol by 11HSD1 in
obese men with and without type 2 diabetes mellitus, so
that coprescription ofmetforminwith selective 11HSD1
inhibitors may maximize the metabolic benefits of these
agents.
Acknowledgments
We acknowledge the support of the Wellcome Trust Clinical
Research Facility in particularKaren Paterson, and thank Sanjay
Kumar Kothiya, Kerry McInnes, Jill Harrison and Lynne Ram-
age for their technical assistance.
Address all correspondence and requests for reprints to: Ro-
land Stimson, University/ BHF Centre for Cardiovascular Sci-
ence, Queen’sMedical Research Institute, 47 Little France Cres-
cent, Edinburgh, Scotland, United Kingdom EH16 4TJ, Tel:
00441312426748; Fax: 00441312426779; Email:
roland.stimson@ed.ac.uk.
This work was supported by Funding: Medical Research
Council, theEdinburghandLothiansHealthFoundationand the
British Heart Foundation.
Disclosure statement: Authors AJA, RA, NZM, GCJ, KS,
DEL and RHS have no duality of interest to declare. BRW is an
inventor on relevant patents held by University of Edinburgh.
Author contributions: AJA, RA, BRW and RHS designed the
experiments; AJA, GCJ, KS and RHS performed the experi-
ments; AJA, RA, NZH, KS, DEL and RHS analyzed the samples
and data; AJA and RHS wrote the manuscript; RA, NZH, GCJ,
KS, DEL and BRW reviewed the manuscript.
References
1. Hundal RS, Krssak M, Dufour S et al. Mechanism by which met-
formin reduces glucose production in type 2 diabetes. Diabetes.
2000;49:2063–2069.
2. Pernicova I, Korbonits M. Metformin–mode of action and clinical
implications for diabetes and cancer. Nat Rev Endocrinol. 2014;
10:143–156.
3. Rena G, Pearson ER, Sakamoto K.Molecular mechanism of action
of metformin: old or new insights? Diabetologia. 2013;56:1898–
1906.
4. Rask E,Olsson T, Soderberg S et al.Tissue-specific dysregulation of
cortisol metabolism in human obesity. J Clin Endocrinol Metab.
2001;86:1418–1421.
5. Rask E, Walker BR, Soderberg S et al. Tissue-specific changes in
peripheral cortisol metabolism in obese women: increased adipose
11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endo-
crinol Metab. 2002;87:3330–3336.
6. Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC,
Walker BR. Increased whole-body and sustained liver cortisol re-
generationby11beta-hydroxysteroid dehydrogenase type 1 in obese
men with type 2 diabetes provides a target for enzyme inhibition.
Diabetes. 2011;60:720–725.
7. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL,
Edwards CRW. Mineralocorticoid activity of liquorice: 11-hy-
droxysteroid dehydrogenase deficiency comes of age.Lancet. 1987;
ii:821–824.
8. Stimson RH, Andersson J, Andrew R et al. Cortisol release from
adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in
humans. Diabetes. 2009;58:46–53.
9. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of
visceral obesity and the metabolic syndrome. Science. 2001;294:
2166–2170.
10. Paterson JM,MortonNM,FievetC et al.Metabolic syndromewith-
out obesity: Hepatic overexpression of 11beta-hydroxysteroid de-
hydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A.
2004;101:7088–7093.
11. SandeepTC,AndrewR,HomerNZ,AndrewsRC, SmithK,Walker
BR. Increased in vivo regeneration of cortisol in adipose tissue in
human obesity and effects of the 11beta-hydroxysteroid dehydro-
genase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872–
879.
12. Dube S, Norby B, Pattan V et al. Hepatic 11beta-hydroxysteroid
dehydrogenase type 1 activity in obesity and type 2 diabetes using a
novel triple tracer cortisol technique.Diabetologia. 2014;57:1446–
1455.
13. JamiesonPM,ChapmanKE,EdwardsCRW, Seckl JR.11-hydrox-
ysteroid dehydrogenase is an exclusive 11-reductase in primary
cultures of rat hepatocytes: effect of physicochemical and hormonal
manipulations. Endocrinology. 1995;136:4754–4761.
14. Anderson A,Walker BR. 11beta-HSD1 inhibitors for the treatment
of type 2 diabetes and cardiovascular disease. Drugs. 2013;73:
1385–1393.
15. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the ac-
tivities of 11beta-hydroxysteroid dehydrogenases in vivo using iso-
topically labelled cortisol. J Clin Endocrinol Metab. 2002;87:277–
285.
16. Stimson RH, Johnstone AM, Homer NZ et al.Dietary macronutri-
ent content alters cortisolmetabolism independently of bodyweight
changes in obese men. J Clin Endocrinol Metab. 2007;92:4480–
4484.
17. McInnes KJ, Andersson TC, Simonyte K et al. Association of 11be-
ta-hydroxysteroid dehydrogenase type I expression and activity
with estrogen receptor beta in adipose tissue from postmenopausal
women. Menopause. 2012;19:1347–1352.
18. Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR.
The contribution of visceral adipose tissue to splanchnic cortisol
production in healthy humans. Diabetes. 2005;54:1364–1370.
19. Basu R, Basu A, Grudzien M et al. Liver is the site of splanchnic
cortisol production in obese nondiabetic humans. Diabetes. 2009;
58:39–45.
20. Hughes KA, Manolopoulos KN, Iqbal J et al. Recycling between
cortisol and cortisone in human splanchnic, subcutaneous adipose,
and skeletal muscle tissues in vivo. Diabetes. 2012;61:1357–1364.
21. Basu R, Singh RJ, Basu A et al. Obesity and type 2 diabetes do not
alter splanchnic cortisol production in humans. J Clin Endocrinol
Metab. 2005;90:3919–3926.
22. Valsamakis G, Anwar A, Tomlinson JW et al. 11beta-hydroxys-
teroid dehydrogenase type 1 activity in lean and obese males with
type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755–
4761.
23. SumCF,Webster JM, JohnsonAB,CatalanoC, Cooper BG,Taylor
R. The effect of intravenous metformin on glucose metabolism dur-
ing hyperglycaemia in type 2 diabetes.Diabet Med. 1992;9:61–65.
6 Metformin increases 11HSD1 in men J Clin Endocrinol Metab
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 August 2016. at 07:25 For personal use only. No other uses without permission. . All rights reserved.
24. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the
normal and diabetic mouse. Xenobiotica. 1994;24:49–57.
25. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA,Will
Y. Biguanide-induced mitochondrial dysfunction yields increased
lactate production and cytotoxicity of aerobically-poised HepG2
cells and human hepatocytes in vitro. Toxicol Appl Pharmacol.
2008;233:203–210.
26. Cho K, Chung JY, Cho SK et al. Antihyperglycemic mechanism of
metformin occurs via the AMPK/LXRalpha/POMC pathway. Sci
Rep. 2015;5:8145.
27. Arslanian SA, Lewy V, Danadian K, Saad R.Metformin therapy in
obese adolescents with polycystic ovary syndrome and impaired
glucose tolerance: amelioration of exaggerated adrenal response to
adrenocorticotropin with reduction of insulinemia/insulin resis-
tance. J Clin Endocrinol Metab. 2002;87:1555–1559.
doi: 10.1210/jc.2016-2069 press.endocrine.org/journal/jcem 7
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 August 2016. at 07:25 For personal use only. No other uses without permission. . All rights reserved.
